Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
Frequently asked questions
What sector does Burzynski Research (BZYR) operate in?
Burzynski Research belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Burzynski Research (BZYR) current stock price?
As of the latest data, Burzynski Research stock price is $0.00, with a previous close of $0.00.
What is Burzynski Research (BZYR) current market capitalization?
Burzynski Research market cap is approximately 26.29 thousand.
What is Burzynski Research (BZYR) Earnings Per Share (EPS)?
The trailing EPS is -$0.01.
Does Burzynski Research (BZYR) pay dividends?
No. Burzynski Research does not pay a dividend.
What is Burzynski Research (BZYR) beta (volatility) score?
Burzynski Research has a beta of 0.431, indicating lower volatility than the overall market.